AACCE Investments
ScreenerStocksIndicesPicksETFsBlogPricing

© 2026 ACCE Investments. All rights reserved.

ACCE Investments - Institutional-grade stock research for retail investors | BetaList
IndicesStocksETFsScreenerBlogGlossaryCompareMarket dataAdvisors
TermsPrivacyCookiesDisclaimerLegal noticeProfessional termsAboutContact
TCBIO

Texas Capital Bancshares Inc. Depositary Shares 5.75% Fixed Rate Non-Cumulative Perpetual Preferred Stock Series B (TCBIO) fair value

Financial Services · Banks - Regional · NASDAQ · United States
$18.28+0.00%
Market cap $3.3BNext earnings 2025-07-16Updated Oct 20, 2026
Our verdict
Trades 52% below our fair value
Price
$18.28
Model fair valueConfidence: good
$37.93
Model range
$19.04 to $56.81
Fair value $37.93
Price $18.28
2 models fit Texas Capital Bancshares Inc. Depositary Shares 5.75% Fixed Rate Non-Cumulative Perpetual Preferred Stock Series B and they disagree: 0 of 2 land within 15% of the average. The price is below every model.
Two or more of our models back this value.
Large discount(i)
Valued as a bank: Residual income, Dividend discount, and Graham number.
ACCE opinionTexas Capital Bancshares Inc. Depositary Shares 5.75% Fixed Rate Non-Cumulative Perpetual Preferred Stock Series B (TCBIO)
Fair value (2 models)
$37.93
ACCE price target
$19.00
Rating
Undervalued
Horizon
12 months
Fair value published on 11 Oct 2026, 00:00 CEST; previously $18.32 since 5 Oct 2026, 00:00 CEST.
ACCE price target published on 11 Oct 2026, 00:00 CEST.
Rating published on 20 Oct 2026, 16:04 CEST.
Price used: $18.28 at the close on 22 Oct 2026, 22:00 CEST.
Models: Dividend discount, Graham number, and Residual income.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Full methodology
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
51.8% below
+107.5% to fair value
ACCE score
59
out of 100
P/E
4.6x
forward 0.0x
1-year return
-10.7%
Dividend yield
1.09%

Texas Capital Bancshares Inc. Depositary Shares 5.75% Fixed Rate Non-Cumulative Perpetual Preferred Stock Series B in four questions

Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
OverviewAsk ACCEValuationQualityAnalystsSmart MoneyCompareNews and Record

Overview

ACCE thesis

Texas Capital Bancshares is a Dallas-based regional bank, and TCBIO is its 5.75% fixed-rate non-cumulative perpetual preferred, represented by depositary shares that each carry a fractional interest in the underlying preferred. The senior claim sits ahead of common equity, so the security's appeal rests on the bank's ability to keep paying its dividend rather than on earnings growth. The reported 8.6% revenue growth and 10.2% ROE point to a bank earning a reasonable return on its equity base, while the 36.7% operating margin and a trailing P/E of 4.6 suggest the market is pricing in meaningful skepticism about that earnings stream. The data available here does not include credit quality, capital ratios or deposit trends, so the first diligence step is to pull the bank's CET1 ratio and its recent provisions to judge whether the preferred coupon is well covered. Given the 59/100 score and no index membership, this name merits a deeper look only if those capital and credit figures hold up.

AI-assisted·How I use AIWritten Oct 18, 2026
⚠ Investor warnings · 1 flagAI-assisted·How I use AI
  • moderate
    Score down 14 points
    ACCE score fell from 73 to 59 over 90 days, with Momentum at 25/100. Growth and quality remain solid, but the trend has weakened.

AI research notes

AI-assisted·How I use AIWritten Oct 14, 2026 · figures from 2026-10-12 · prices to Oct 22, 2026
Why it could do well
  • The preferred pays a 7.9% dividend yield at the current price.
  • Free cash flow over the last twelve months came to $348M, with a 10.5% free cash flow yield.
  • Consensus fair value of $37.97 sits 109.5% above the $18.12 share price.
Why it could disappoint
  • Return on equity of 10.2% is modest, and the consensus fair value rests on only 2 of 3 valuation models.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Ask ACCE

Valuation

INVESTOR
Where TCBIO's valuation models land
Price
$18.28
Model fair value
$37.93
Model range
$19.04 to $56.81
Fair value $37.93
Price $18.28
The price is below the whole model range.
Model
Fair value
Upside
Dividend discount
Graham number
Residual income
Create a free account: 5 full stock pages a month, no card.

See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.

  • +A plain reason under every score
  • +Conviction breakdown and growth / value / quality / momentum scores
  • +Score history: how each score moved over time

Analysts

Wall Street consensus

No analyst coverage yet.
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO

In one line

Trades are only made public after a delay. We show the delay so you know how old the news is.

Company insiders
No trades filed
Last 90 days
Congress
No trades filed
Last 180 days
Average delay
No trades filed
From trade to public filing
Do politicians beat the market? Our backtest →
Smart money tracking PRO FEATURE

Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Every insider and Congress trade, with how late it was disclosed
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

News and Record

Press releases mentioning this company

Recent performance

1 week
+0.0%
1 month
-5.1%
3 months
-10.3%
6 months
-16.5%
YTD
-9.0%
1 year
-10.7%

SEC filings

Recommendation history, last 12 months

DateTypeNewPreviousPrice
20 Oct 2026, 16:04 CESTRatingUndervaluedfirst publication$18.28
11 Oct 2026, 00:00 CESTFair value$37.97$18.32$18.28
11 Oct 2026, 00:00 CESTACCE price target$19.00first publication$18.28
5 Oct 2026, 00:00 CESTFair value$18.32$17.95$18.90
30 Sept 2026, 00:00 CESTFair value$17.95$29.49$18.35
28 Sept 2026, 00:00 CESTFair value$29.49$19.13$18.64
26 Sept 2026, 00:00 CESTFair value$19.13$19.93$18.86
14 Sept 2026, 00:00 CESTFair value$19.93$20.70$19.71
9 Sept 2026, 00:00 CESTFair value$20.70$21.03$19.90
6 Sept 2026, 00:00 CESTFair value$21.03$34.90$19.90

This analysis is not personalised investment advice and does not take your situation, objectives or risk tolerance into account. ACCE Investments is not an authorised investment firm.

Investing in shares carries a risk of losing capital. The value of an investment can go down as well as up.

Valuation horizon: 12 months from the publication date.

Conflicts of interest. ACCE Investments is operated by Adrien Chantreuil, who may hold personal positions in the securities analysed. Positions are declared on each security. ACCE receives no payment from the companies analysed or from any intermediary for this analysis.

Get the full TCBIO page, free

Every model, the scenarios, fair value history, AI notes and the four questions. 5 full stock pages every month on the free plan, no card.

Free accounts get 5 full stock pages a month, including the full page.

Snapshot

Growth68Value59Quality85Momentum25Total59
Valuation
Trailing P/E
4.6x
Forward P/E
0.0x
PEG
0.29
P/B
0.00x
EV / Revenue
0.0x
Book value/sh
$77.01
Enterprise value
$-1,611,906,816
Profitability
ROE
10.2%
FCF yield
10.61%
ROIC
5.9%
Health and risk
Debt / equity
0.26
Dividend yield
1.09%
Beta
0.63

Price

-10.8% · 1Y

Ask anything about TCBIO

Answered from Texas Capital Bancshares Inc. Depositary Shares 5.75% Fixed Rate Non-Cumulative Perpetual Preferred Stock Series B fundamentals + recent valuations. Every number shows its source and date.

This stock Peer Peer median weaker → stronger
P/Ebetter than 100% of peers
low 4.6x4.6xhigh 15.4x
ROEbetter than 83% of peers
low 7%10%high 10%
Div yieldbetter than 50% of peers
low 0.0%1.1%high 5.7%

Peers

Prices Oct 22, 2026
CompanyPriceFair valuevs fair valueP/EROEQualityScore
TCBIO Texas Capital Bancshares Inc. Depositary Shares 5.75% Fixed Rate Non-Cumulative Perpetual Preferred Stock Series B$18.28$3852% below4.6x10.2%8559
BBAR.BA BBVA Banco Frances SAARS 7240.00--11.0x8.1%7168
BMA.BA Banco Macro SA BARS 10870.00--15.4x7.1%7957
BOGOTA.CL Banco de BogotaCOP 38240.00--9.0x9.2%6149
PFDAVVNDA.CL Davivienda Group preferredCOP 28740.00--8.2x10.3%5382
ITAUCL.SN Banco Itau ChileCLP 22500.00--12.3x9.4%8171
PFAVAL.CL Grupo Aval preferredCOP 780.00--10.8x10.0%5871

Sector report card

Where TCBIO ranks against its sector peers on each metric.

Computing percentiles…
  • GlobeNewswire•Oct 8, 2026
    Texas Capital Bancshares, Inc. Now Trading on the Texas Stock Exchange
  • GlobeNewswire•Oct 7, 2026
    Texas Capital Bancshares, Inc. Announces Date for Q3 2026 Operating Results
  • PR Newswire•Oct 1, 2026
    Linea Energy Closes Project Debt Financing and Preferred Equity Commitment for 250 MW / 500 MWh Mesa View BESS in Texas
7 more press releases · full archive on Investor+.INVESTOR
40 filings
October 2026
Oct 22
10-QQuarterly reportPeriod 2026-09-30
View on SEC →
Oct 21
8-KCurrent reportPeriod 2026-10-21
View on SEC →
September 2026
Sep 16
8-KCurrent reportPeriod 2026-09-16
View on SEC →
37 more filings + AI summaries on Investor+.INVESTOR